





Amjad Bani Hani

Associate Prof. of Cardiac Surgery and Intensive Care

CABG

INTRODUCTION

- HISTORY OF CARDIAC SURGERY
- CORONARY ARTERY ANATOMY
- MANAGEMENT
- SURGICAL TECHNIQUES

INTRODUCTION

- HISTORY OF CARDIAC SURGERY
- CORONARY ARTERY ANATOMY
- MANAGEMENT
- SURGICAL TECHNIQUES

Adult Cardiac Surgery: Ischemic Heart Disease

Alexis Carrel-

"In certain cases of angina pectoris, when the mouth of the coronary is calcified, it would be useful to establish a complementary circulation for the lower part of the arteries. I attempted to perform an ... anastomosis between the descending aorta and the left coronary. It was, for many reasons, a difficult operation."

American Surgical Association, 1910

Claude Beck


• 1930's- sought to increase myocardial blood flow indirectly with pericardial fat and omentum.

Arthur Vineberg

- 1940's- Mobilization of left internal mammary artery with implantation of bleeding end into the left ventricle.
- 1964- follow-up study on 140 patients

33% mortality

85% relief from angina



Mason Sones,

1950's- cine coronary arteriography.

1962- direct and reproducible catheterization of the coronary arteries.


"Collectively, all of the cardiological advances in this century pale in comparison with this priceless achievement."

Floyd Loop, MD


John H. Gibbon, Jr.

"During the long night, helplessly watching the patient struggle for life as her blood became darker and her veins more distended, the idea naturally occurred to me that if it were possible to remove some of the blue blood...put oxygen into that blood and allow carbon dioxide to escape from it, and then to inject continuously the now-red blood back into the patient's arteries, we might have saved her life."

- Heart-lung machine
- May 6, 1953-ASD closure



Heart Lung Machine





- 1962- David C. Sabiston, Jr.-
 - Aortocoronary saphenous vein bypass
- 1964-KOLOSOV LIMA -LAD IN Russia

Adult Cardiac Surgery: Ischemic Heart Disease (CABG)

• Early and widespread acceptance of coronary bypass was delayed.

• Best known cooperative studies (1970-80's) were the;

VA


Coronary Artery Surgery Study

European Coronary Surgery Study


INTRODUCTION

- HISTORY OF CARDIAC SURGERY
- CORONARY ARTERY ANATOMY
- MANAGEMENT
- SURGICAL TECHNIQUES


Coronary Anatomy




Coronary Anatomy





Coronary Anatomy




The Normal Heart - Coronary Artery Anatomy


















INTRODUCTION

- HISTORY OF CARDIAC SURGERY
- CORONARY ARTERY ANATOMY
- MANAGEMENT
- SURGICAL TECHNIQUES

Management

- Indication For Surgery
- Preoperative Evaluation
- Conduits decision
- Operation Decision
- ERAS

Indications for Coronary Artery Bypass Grafting: (CABG)

- Triple vessel disease with DM and decreased EF
- Lf main coronary artery disease (Distal)
- Hi risk PCI or not Suitable for PCI
- Complications of PTCA
- Mechanical complications of MI
- Anomalies of Coronary arteries.

Table 2. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated May 2019)



CLASS 1 (STRONG)	Benefit >>> Risk
Suggested phrases for writing recommenda Is recommended Is indicated/useful/effective/beneficial Should be performed/administered/other Comparative-Effectiveness Phrases†: Treatment/strategy A is recommended/in treatment B Treatment A should be chosen over treat	ndicated in preference to
CLASS 2a (MODERATE)	Benefit >> Risk
Suggested phrases for writing recommenda Is reasonable Can be useful/effective/beneficial Comparative-Effectiveness Phrases†: Treatment/strategy A is probably recompreference to treatment B It is reasonable to choose treatment A or	nended/indicated in
CLASS 2b (WEAK)	Benefit ≥ Risk
Suggested phrases for writing recommenda May/might be reasonable May/might be considered Usefulness/effectiveness is unknown/uncle established	
CLASS 3: No Benefit (MODERATE) (Generally, LOE A or B use only)	Benefit = Risk
Suggested phrases for writing recommenda Is not recommended Is not indicated/useful/effective/beneficial Should not be performed/administered/oth	
Should not be performed/administered/our	
Class 3: Harm (STRONG)	Risk > Benefit

LEVEL (QUALITY) OF EVIDENCE‡ LEVEL A . High-quality evidence from more than 1 RCT Meta-analyses of high-quality RCTs • One or more RCTs corroborated by high-quality registry studies LEVEL B-R (Randomized) Moderate-quality evidence‡ from 1 or more RCTs . Meta-analyses of moderate-quality RCTs LEVEL B-NR (Nonrandomized) . Moderate-quality evidence from 1 or more well-designed, wellexecuted nonrandomized studies, observational studies, or registry · Meta-analyses of such studies LEVEL C-LD (Limited Data) Randomized or nonrandomized observational or registry studies with limitations of design or execution · Meta-analyses of such studies · Physiological or mechanistic studies in human subjects LEVEL C-EO (Expert Opinion)

COR and LOE are determined independently (any COR may be paired with any LOE).

Consensus of expert opinion based on clinical experience

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

- The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).
- For comparative-effectiveness recommendations (COR 1 and 2a; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
- ‡ The method of assessing quality is evolving, including the application of standardized, widely-used, and preferably validated evidence grading bods; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence: NR. nonrandomized; R. randomized; and RCT, randomized controlled trial.



Revascularization in SIHD



Revascularization to Improve Survival in SIHD Compared With Medical Therapy



Reco	Recommendations for Revascularization to Improve Survival in SIHD Compared With Medical Therapy		
	Referenced studies that support the recommendations are summarized in Online Data Supplement 10.		
COR	LOE	Recommendations	
	Left ventricular dysfunction and multivessel CAD		
		1. In patients with SIHD and multivessel CAD appropriate for CABG with severe left	
1	B-R	ventricular systolic dysfunction (left ventricular ejection fraction <35%), CABG is	
		recommended to improve survival.	
		2. In selected patients with SIHD and multivessel CAD appropriate for CABG and	
		mild-to-moderate left ventricular systolic dysfunction (ejection fraction 35%–50%),	
2a	B-NR	CABG (to include a left internal mammary artery [LIMA] graft to the LAD) is	
		reasonable to improve survival.	



Revascularization to Improve Survival in SIHD Compared With Medical Therapy (con't.)

Left main CAD		
1	B-R	3. In patients with SIHD and significant left main stenosis, CABG is recommended to improve survival.
2a	B-NR	4. In selected patients with SIHD and significant left main stenosis for whom PCI can provide equivalent revascularization to that possible with CABG, PCI is reasonable to improve survival.



Revascularization to Improve Survival in SIHD Compared With Medical Therapy (con't.)

Multivessel CAD		
2 b	B-R	5. In patients with SIHD, normal ejection fraction, significant stenosis in 3 major coronary arteries (with or without proximal LAD), and anatomy suitable for CABG, CABG may be reasonable to improve survival.
2 b	B-R	6. In patients with SIHD, normal ejection fraction, significant stenosis in 3 major coronary arteries (with or without proximal LAD), and anatomy suitable for PCI, the usefulness of PCI to improve survival is uncertain.



Revascularization to Improve Survival in SIHD Compared With Medical Therapy (con't.)


Stenosis in the proximal LAD artery			
2b	B-R	7. In patients with SIHD, normal left ventricular ejection fraction, and significant stenosis in the proximal LAD, the usefulness of coronary revascularization to improve survival is uncertain.	
	Single- or double-vessel disease not involving the proximal LAD		
3: No Benefit	B-R	8. In patients with SIHD, normal left ventricular ejection fraction, and 1- or 2-vessel CAD not involving the proximal LAD, coronary revascularization is not recommended to improve survival.	



Figure 6. Revascularization in patients with SIHD.

Colors correspond to Table 2.

CABG indicates coronary artery bypass graft; CAD, coronary artery disease; EF, ejection fraction; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; and GDMT, guideline-directed medical therapy.





Situations in Which CABG Would Be Preferred





Patients With Complex Disease

Recommendations for Patients With Complex Disease

Referenced studies that support the recommendations are summarized in Online Data Supplement 13.

COR	LOE	Recommendations
1	B-R	1. In patients who require revascularization for significant left main CAD with high-complexity CAD, it is recommended to choose CABG over PCI to improve survival.
2a	B-R	2. In patients who require revascularization for multivessel CAD with complex or diffuse CAD (e.g., SYNTAX score >33), it is reasonable to choose CABG over PCI to confer a survival advantage.


Patients With Diabetes




Recommendations for Patients With Diabetes

Referenced studies that support the recommendations are summarized in Online Data Supplement 14.


	Referenced studies that support the recommendations are summarized in Online Data Supplement 14.	
COR	LOE	Recommendations
		1. In patients with diabetes and multivessel CAD with the involvement of the LAD, who
1	A	are appropriate candidates for CABG, CABG (with a LIMA to the LAD) is
		recommended in preference to PCI to reduce mortality and repeat revascularizations.
		2. In patients with diabetes who have multivessel CAD amenable to PCI and an
2a	B-NR	indication for revascularization and are poor candidates for surgery, PCI can be useful
		to reduce long-term ischemic outcomes.
		3. In patients with diabetes who have left main stenosis and low- or intermediate-
2 b	B-R	complexity CAD in the rest of the coronary anatomy, PCI may be considered an
		alternative to CABG to reduce major adverse cardiovascular outcomes.








- A 50-year-old male patient
- Diabetic on OHA (Metformin)
- Hypertensive on BB and CCB
- Dyslipidemia on Statin and aspirin
- Presented to the ER with ACS (Unstable Angina)
- He was started on Clopidogrel and admitted for further evaluation







- Cath showed
 - Distal Left Main Stenosis
 - RCA stenosis

Factors for Consideration by the Heart Team

Coronary Anatomy

- Left main disease
- Multivessel disease
- High anatomic complexity (i.e., bifurcation disease, high SYNTAX score)

Comorbidities

- Diabetes
- Systolic dysfunction
- Coagulopathy
- Valvular heart disease
- Frailty
- Malignancy
- ESRD
- COPD

- Immunosuppression
- Debilitating neurological disorders
- Liver disease/ cirrhosis
- Prior CVA
- Calcified aorta
- Aortic aneurysm

Procedural Factors

- Local and regional outcomes
- Access site for PCI
- Surgical risk
- PCI risk

Patient Factors

- Unstable presentation or shock
- Patient preferences
- Inability or unwillingness to adhere to DAPT
- Religious beliefs
- Patient education, knowledge, and understanding

Guiding Principle: Ideal situations for Heart Team consideration include patients with complex coronary disease, comorbid conditions that could impact the success of the revascularization strategy, and other clinical or social situations that may impact outcomes.



Improving Equity of Care in Revascularization



Health disparities by sex and race are evident across the spectrum of CVD in the United States.



Women and non-White patients are less likely to receive guideline-based therapies.



Women and non-White patients derive comparable benefit from revascularization after controlling for other factors.




In patients who require coronary revascularization, treatment decisions should be based on clinical indication, regardless of sex or race or ethnicity, and efforts to reduce disparities of care are warranted (Class 1).



Abbreviations: CVD indicates cardiovascular disease.

Assessing Risk for Patients Undergoing CABG



Risk Factors Not Quantified in the STS Score		
Cirrhosis	Meld	
Frailty	Gait Speed	
Malnutrition	MUST	

ssociation

Guiding Principle: In patients who are being considered for CABG, calculation of the STS \ Euro II risk score is recommended to help stratify patient risk. The MELD score, gait speed, and the MUST score may help in patients with cirrhosis, frailty, and malnutrition respectively.

Abbreviations: CABG indicates coronary artery bypass grafting; MELD, Model for End-Stage Liver Disease; MUST, Malnutrition Universal Screening Tool; and STS, Society of Thoracic Surgeons.



INDICATION??



Revascularization to Improve Survival in SIHD Compared With Medical Therapy (con't.)

Left main CAD		
1	B-R	3. In patients with SIHD and significant left main stenosis, CABG is recommended to improve survival.
2a	B-NR	4. In selected patients with SIHD and significant left main stenosis for whom PCI can provide equivalent revascularization to that possible with CABG, PCI is reasonable to improve survival.

Patients With Diabetes



Recommendations for Patients With Diabetes

Referenced studies that support the recommendations are summarized in Online Data Supplement 14.

	Referenced studies that support the recommendations are summarized in Offine Data Supplement 14.	
COR	LOE	Recommendations
		1. In patients with diabetes and multivessel CAD with the involvement of the LAD, who
1	A	are appropriate candidates for CABG, CABG (with a LIMA to the LAD) is
		recommended in preference to PCI to reduce mortality and repeat revascularizations.
		2. In patients with diabetes who have multivessel CAD amenable to PCI and an
2a	B-NR	indication for revascularization and are poor candidates for surgery, PCI can be useful
		to reduce long-term ischemic outcomes.
		3. In patients with diabetes who have left main stenosis and low- or intermediate-
2 b	B-R	complexity CAD in the rest of the coronary anatomy, PCI may be considered an
,		alternative to CABG to reduce major adverse cardiovascular outcomes.

- Indication For Surgery
- Preoperative Evaluation
- Conduits decision
- Operation Decision
- ERAS

- Respiratory Evaluation
- Renal Evaluation
- Infection Evaluation
- Carotids
- Frailty
- Risk Assessment

- Liver
- Thyroid
- Medications
- Coagulopathy

Perioperative Pharmacotherapy

Pre-op Anti-platelet

PRE-OP ANTI-PLATELET	PLAN TO DECREASE RISK OF BLEEDING
ASA, daily	CONTINUE, if already taking (Class 1)
	STOPAt least 24 hrs, if URGENT (Class 1)
Clopidogrel & Ticagrelor	Ticagrelor at least 3d, if elective (Class 2a) Clopidogrel at least 5d, if elective (Class 2a) Prasugrel at least 7d, if elective (Class 2a)
Eptifibatide & Tirofiban	STOP At least 4 hrs (Class 1)
Abciximab	STOP At least 12 hrs (Class 1)

Anti-Arrhythmics* Preop

BB and Amiodarone can reduce the incidence of post-op afib (Class 2a)


BB may reduce mortality or postop complications (Class 2b)




Abbreviations: AFIB indicates atrial fibrillation; ASA, aspirin; BB, beta blockers; D, days; and HRS, hours.


^{*} In patients with no contraindications to usage

Patients Undergoing Other Cardiac Surgery and Operative Approach



Source: This Photo by Unknown Author is licensed under CC BY-







Source: This Photo by Unknown Author is licensed under CC BY-NC



Abbreviations: CABG indicates coronary artery bypass grafting; and CAD, coronary artery disease.

Shared Decision-Making and Informed Consent



Informed Consent

Clinician provides the best available evidence for treatment options, including the risks & benefits of each option



Patient-Centered Care

Treatment & care options take into consideration individual values & preferences



Shared Decision-Making

A collaborative decision about treatment or care is documented and shared with relevant stakeholders

COR	RECOMMENDATIONS
1	In patients undergoing revascularization, decisions should be patient centered—that is, considerate of the patient's preferences and goals, cultural beliefs, health literacy, and social determinants of health—and made in collaboration with the patient's support system.
1	In patients undergoing coronary angiography or revascularization, adequate information about benefits, risks, therapeutic consequences, and potential alternatives in the performance of percutaneous and surgical myocardial revascularization should be given, when feasible, with sufficient time for informed decision-making to improve clinical outcomes.



Table 8. Patient Clinical Status Definitions to Guide Revascularization

Elective

Cardiac function has been stable in the days-weeks before intervention. The intervention could be deferred without increased risk of compromise to cardiac outcome.

Urgent

Intervention is required during the same hospitalization to minimize chance of further clinical deterioration. Examples include worsening sudden chest pain, heart failure, acute myocardial infarction, anatomy, intra-aortic balloon pump, unstable angina, with intravenous nitroglycerin, or rest angina.

Emergency

Patients requiring emergency intervention will have ongoing, refractory, unrelenting cardiac compromise, with or without hemodynamic instability, and not responsive to any form of therapy except cardiac intervention. There should be no delay in providing operative intervention.

Emergency/s alvage

Patients requiring emergency/salvage intervention are those who require cardiopulmonary resuscitation in route to intervention, before induction of anesthesia or who require extracorporeal membrane oxygenation to maintain life.





General Procedural Issues for CABG




- Indication For Surgery
- Preoperative Evaluation
- Conduits decision
- Operation Decision
- ERAS


Conduites

- Arterial
 - LIMA
 - RIMA
 - RA
 - GEA
 - IEA

- Venous
 - GSV
 - SSV
 - Arm Veins




(a)





















Arterial vs Venous conduits






Bypass Conduits in Patients Undergoing CABG

Radial artery


Recommended in preference to a saphenous vein conduit to graft the second most important, significantly stenosed, non–LAD vessel (Class 1)



Source: This Photo by Unknown Author is licensed under CC BY-SA


IMA (prefer left)

To LAD (Class 1)



Source: This Photo by Unknown Author is licensed under CC BY-SA

BIMA



Improves
Iong-term outcomes
when procedure is
done by experienced
operators
(Class 2a)

Source: https://vpjournal.net/article/view/3141

Click here for more best practices



Abbreviations: BIMA indicates bilateral internal mammary artery; IMA, internal mammary artery; LAD, left anterior descending; and SVG, saphenous vein graft...

The New England Journal of Medicine

Copyright, 1986, by the Massachusetts Medical Society

Volume 314

JANUARY 2, 1986


Number 1

INFLUENCE OF THE INTERNAL-MAMMARY-ARTERY GRAFT ON 10-YEAR SURVIVAL AND OTHER CARDIAC EVENTS

FLOYD D. LOOP, M.D., BRUCE W. LYTLE, M.D., DELOS M. COSGROVE, M.D., ROBERT W. STEWART, M.D., MARLENE GOORMASTIC, M.P.H., GEORGE W. WILLIAMS, Ph.D., LEONARD A.R. GOLDING, M.D., CARL C. GILL, M.D., PAUL C. TAYLOR, M.D., WILLIAM C. SHELDON, M.D., AND WILLIAM L. PROUDFIT, M.D.

Abstract We compared patients who received an internal-mammary-artery graft to the anterior descending coronary artery alone or combined with one or more saphenous-vein grafts (n = 2306) with patients who had only saphenous-vein bypass grafts (n = 3625). The 10-year actuarial survival rate among the group receiving the internal-mammary-artery graft, as compared with the group who received the vein grafts (exclusive of hospital deaths), was 93.4 percent versus 88.0 percent (P = 0.05) for those with one-vessel disease; 90.0 percent versus 79.5 percent (P<0.0001) for those with two-vessel disease; and 82.6 percent versus 71.0 percent (P<0.0001) for those with three-vessel disease. After an adjustment for demographic and clinical differences by Cox multivariate analysis, we

found that patients who had only vein grafts had a 1.61 times greater risk of death throughout the 10 years, as compared with those who received an internal-mammary-artery graft. In addition, patients who received only vein grafts had 1.41 times the risk of late myocardial infarction (P<0.0001), 1.25 times the risk of hospitalization for cardiac events (P<0.0001), 2.00 times the risk of cardiac reoperation (P<0.0001), and 1.27 times the risk of all late cardiac events (P<0.0001), as compared with patients who received internal-mammary-artery grafts. Internal-mammary-artery grafting for lesions of the anterior descending coronary artery is preferable whenever indicated and technically feasible. (N Engl J Med 1986; 314:1-6.)




Loop FD et al NEJM 1986

Two internal thoracic artery grafts are better than one


Bruce W. Lytle, MD, Eugene H. Blackstone, MD, Floyd D. Loop, MD, Penny L. Houghtaling, MS, John H. Arnold, MD, Rami Akhrass, MD, Patrick M. McCarthy, MD, Delos M. Cosgrove, MD

The Journal of Thoracic and Cardiovascular Surgery
Volume 117 Issue 5 Pages 855-872 (May 1999)
DOI: 10.1016/S0022-5223(99)70365-X












Arterial conduits used for coronary artery bypass grafting

- Internal Thoracic Artery
- Radial Artery
- Right Gastroepiploic Artery
- Inferior Epigastric Artery
- Others



A meta-analysis comparing bilateral internal mammary artery with left internal mammary artery for coronary artery bypass grafting


Aaron J. Weiss^{1,2}, Shan Zhao³, David H. Tian², David P. Taggart⁴, Tristan D. Yan^{2,5}

¹Department of Cardiothoracic Surgery, Mount Sinai School of Medicine, New York City, New York, USA; ²The Collaborative Research (CORE) Group, Sydney, Australia; ³Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York City, New York, USA; ⁴Department of Cardiae Surgery, John Radeliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK; ⁵Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia

Corresponding to: Aaron J. Weiss, M.D. Department of Cardiothoracie Surgery, Mount Sinai Medical Center, 1190 Fifth Avenue Box 1029, New York, NY 10029, USA. Email: aaron.weiss@mountsinai.org.

			BIMA	LIMA		Hazard Ratio		Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	Total	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Naunheim	-0.288	0.265	100	100	1.7%	0.75 [0.45, 1.26]	1992	
Dewar	0.01	0.272	377	765	1.6%	1.01 [0.59, 1.72]	1995	
Pick	-0.198	0.247	160	161	1.9%	0.82 [0.51, 1.33]	1997	
Buxton	-0.342	0.127	1269	1557	4.9%	0.71 [0.55, 0.91]	1998	
Jones	-0.288	0.181	172	338	3.1%	0.75 [0.53, 1.07]	2000	
Tarelli	0.02	0.349	150	150	1.0%	1.02 [0.51, 2.02]	2001	
Berreklouw	-0.274	0.301	249	233	1.4%	0.76 [0.42, 1.37]	2001	
Endo	-0.051	0.179	443	688	3.1%	0.95 [0.67, 1.35]	2001	
Danzer	-1.347	0.639	382	139	0.3%	0.26 [0.07, 0.91]	2001	
Hirotani	-1.386	0.805	179	124	0.2%	0.25 [0.05, 1.21]	2003	+
Stevens	-0.431	0.106	1808	2498	5.8%	0.65 [0.53, 0.80]	2004	
Calafiore	0.642	0.367	570	570	1.0%	1.90 [0.93, 3.90]	2004	
Lytle	-0.301	0.071	1152	1152	7.9%	0.74 [0.64, 0.85]	2004	~
Toumpoulis	-0.117	0.126	490	490	4.9%	0.89 [0.69, 1.14]	2006	-
Bonacchi	-0.58	0.306	320	332	1.3%	0.56 [0.31, 1.02]	2006	
Mohammadi	-3.912	1.528	1388	9566	0.1%	0.02 [0.00, 0.40]	2008	←
Carrier	-0.431	0.119	1235	5420	5.2%	0.65 [0.51, 0.82]	2009	
Kurlansky	-0.186	0.047	2215	2369	9.3%	0.83 [0.76, 0.91]	2010	-
Kieser	-0.117	0.103	1038	4029	6.0%	0.89 [0.73, 1.09]	2011	
Locker	-0.315	0.107	1153	1153	5.8%	0.73 [0.59, 0.90]	2012	
Puskas	-0.431	0.155	812	2715	3.8%	0.65 [0.48, 0.88]	2012	
Kinoshita	-0.58	0.291	217	217	1.4%	0.56 [0.32, 0.99]	2012	
Kelly	-0.198	0.096	1079	6554	6.4%	0.82 [0.68, 0.99]	2012	
Joo	-0.01	0.169	366	366	3.4%	0.99 [0.71, 1.38]	2012	+
Grau	-0.4	0.115	928	928	5.4%	0.67 [0.54, 0.84]	2012	
Glineur	-0.301	0.127	297	291	4.9%	0.74 [0.58, 0.95]	2012	
Parsa	-0.051	0.065	728	16881	8.2%	0.95 [0.84, 1.08]	2013	+
Total (95% CI)			19277	59786	100.0%	0.78 [0.72, 0.84]		•
Heterogo beityn Tagar	oOardhovazoo,lo	1= 26 36	eno.olo		_	0.2 0.5 1 2 5		
Test for overall effect:	Z = 6.61 (P < 0.0000	1)				Favours [BIMA] Favours [LIMA]		

Effects of bilateral internal mammary artery grafting on long-term survival.



Gijong Yi et al. Circulation. 2014;130:539-545



Study or Subgroup			Sapher Events	nous vein Total	Weight	Odds Ratio M-H,Fixed,95% C	Odds Ratio I M-H, Fixed, 95% Cl	
Cardiac death								
Song SW 2012	0	35	1	25	14.4%	0.23 [0.01, 5.88]		
Deb S 2012	0	510	1	510	12.5%	0.33 [0.01, 8.19]		
Goldman S 2011	1	367	2	366	16.7%	0.50 [0.04, 5.51]	-	
Muneretto C 2004	3	48	5	80	40.2%	0.58 [0.13, 2.53]		
Hayward PA 2011	4	113	2	112	16.2%	2.02 [0.36, 11.25]	 -	
Total (95% Cl)		1105		1093	100.0%	0.72 [0.30, 1.73]	•	
Total events	8		11					
Heterogeneity: Chi ² = 2	2.25, df =	4 (P = 0	.69); I ² = ()%			 	
Test for overall effect: 2	Z = 0.74 (P = 0.46))				0.01 0.1 1 10 100 Radial artery Saphenous vein	
Myocardial infarction								
Deb S 2012	2	510	3	510	16.1%	0.67 [0.11, 4.00]		
Goldman S 2011	5	367	4	366	12.2%	1.25 [0.33, 4.69]		
Hayward PA 2011	4	113	5	112	20.8%	0.99 [0.24, 4.06]	_ _	
Muneretto C 2004	2	80	8	80	41.9%	0.23 [0.05, 1.12]		
Song SW 2012	0	35	0	25		Not estimable		
Total (95% Cl)		1105		1093	100.0%	0.68[0.33, 1.38]	•	
Total events	13		19					
Heterogeneity: Chi2= 2		-		96				
Test for overall effect: $Z = 1.08$ ($P = 0.28$)							0.01 0.1 1 10 100	
							Radial artery Saphenous vein	
Repeat coronary oper	ation						I	
Deb S 2012	3	510	12	510	39.4%	0.25 [0.07, 0.88]	 ■	
Goldman S 2011	4	367	6	366	19.6%	0.66 [0.19, 2.36]		
Hayward PA 2011	1	113	4	112	13.1%	0.24 [0.03, 2.19]		
Muneretto C 2004	0	80	8	80	27.9%	0.05 [0.00, 0.93]	←	
Total (95% Cl)		1070		1068	100.0%	0.27[0.13, 0.58]	•	
Total events	8		30					
Heterogeneity: Chi ² = 3.15, df = 3 (P = 0.37); I ² = 5%								
Test for overall effect: 2							0.01 0.1 1 10 100	
							Radial artery Saphenous vein	



Comparison of radial artery versus saphenous vein for clinical outcomes

Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery Insights From PREVENT IV

Connie N. Hess, MD, MHS; Renato D. Lopes, MD, PhD; C. Michael Gibson, MD; Rebecca Hager, MR; Daniel M. Wojdyla, MSc; Brian R. Englum, MD; Michael J. Mack, MD; Robert M. Califf, MD; Nicholas T. Kouchoukos, MD; Eric D. Peterson, MD, MPH; John H. Alexander, MD, MHS

Background—Coronary artery bypass grafting success is limited by vein graft failure (VGF). Understanding the factors associated with VGF may improve patient outcomes.

Methods and Results—We examined 1828 participants in the Project of Ex Vivo Vein Graft Engineering via Transfection IV (PREVENT IV) trial undergoing protocol-mandated follow-up angiography 12 to 18 months post—coronary artery bypass grafting or earlier clinically driven angiography. Outcomes included patient- and graft-level angiographic VGF (≥75% stenosis or occlusion). Variables were selected by using Fast False Selection Rate methodology. We examined relationships between variables and VGF in patient- and graft-level models by using logistic regression without and with generalized estimating equations. At 12 to 18 months post—coronary artery bypass grafting, 782 of 1828 (42.8%) patients had VGF, and 1096 of 4343 (25.2%) vein grafts had failed. Demographic and clinical characteristics were similar between patients with and without VGF, although VGF patients had longer surgical times, worse target artery quality, longer graft length, and they more frequently underwent endoscopic vein harvesting. After multivariable adjustment, longer surgical duration (odds ratio per 10-minute increase, 1.05; 95% confidence interval, 1.03–1.07), endoscopic vein harvesting (odds ratio, 1.41; 95% confidence interval, 1.16–1.71), poor target artery quality (odds ratio, 1.43; 95% confidence interval, 1.07–1.69) were associated with patient-level VGF. The predicted likelihood of VGF in the graft-level model ranged from 12.1% to 63.6%.


Conclusions—VGF is common and associated with patient and surgical factors. These findings may help identify patients with risk factors for VGF and inform the development of interventions to reduce VGF.


Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00042081.
(Circulation. 2014;130:1445-1451.)

Prevalence and Variability of Internal Mammary Artery Graft Use in Contemporary Multivessel Coronary Artery Bypass Graft Surgery

Analysis of the Society of Thoracic Surgeons National Cardiac Database

Minoru Tabata, MD, MPH; Joshua D. Grab, MS; Zain Khalpey, Sean M. O'Brien, PhD; Lawrence H. Cohn, MD; R. !








- Indication For Surgery
- Preoperative Evaluation
- Conduits decision
- Operation Decision
- ERAS

- Conduits combination
- ON Pump Vs OFF Pump


Total arterial revascularization









Fourth Year Cardiovascular System Lectures




Fourth Year Cardiovascular System Lectures



Fourth Year Cardiovascular System Lectures



Fourth Year Cardiovascular System Lectures



Management

- Indication For Surgery
- Preoperative Evaluation
- Conduits decision
- Operation Decision
- ERAS

Active Patient Involvement Preoperative Intraoperative Postoperative Targeted patient education Short-acting anesthetics Multimodal analgesia Medical and nutritional optimization Goal-directed fluid therapy Multimodal analgesia Anemia optimization Early extubation Lung protective ventilation Correction of HgbA1C Antifibrinolytics Early mobility Avoidance of hyperthermia Smoking and alcohol cessation Delirium management Shortened fasting Infection reduction bundle Glycemic control Goal-directed fluid therapy Carbohydrate load Avoidance of hypothermia Antibiotic prophylaxis Thromboprophylaxis Early drain and Foley removal Multidisciplinary Collaboration

ERAS CARDIAC PERIOPERATIVE COMPONENTS

- 1. Preop Education
 - 2. Prehabilitation
 - 3. Smoking and Alcohol Cessation
 - 4. Nutrition Optimization

DAY OF SURGERY

- 5. NPO After Midnight
 - 6. Carbohydrate Clear Drink 2-4 Hours Preop
 - 7. Multimodal Analgesia Initiation







- 9. Continue Multimodal Analgesia
 - 10. Minimize Crystalloid
 - 11. NO BUGS Normothermia (T>36°C) Oxygenation (FiO₂>0.8) anti-Biotic drug/dose(s)/timing Underventilation (ETCO₂>38) • Glycemic control (Glc<180mg/dL) • Skin prep (CHG)/no Shaving
 - 12. PONV Prophylaxis Initiated
 - 13. Postop Sedation Started



14. Continue Multimodal Analgesia

PREOPERATIVE

COMPONENTS

15. Early Extubation

16. Continue PONV Prophylaxis

17. Diet/Bowel Regimen

18. Early Ambulation

19. Line/Drain Removal 20. Priority Discharge




INTRODUCTION

- HISTORY OF CARDIAC SURGERY
- CORONARY ARTERY ANATOMY
- MANAGEMENT
- •SURGICAL TECHNIQUES


Sternotomy


- Sternotomy approach
 - allows almost all cardiac procedures
 - best overall access to the heart
- The sternum is divided with a saw



From: Manual of Cardiac Surgery, Harlan & Starr, Springer-Verlag, New York, 1995


CORONARY ARTERY BYPASS





Fourth Year Cardiovascular System Lectures

Coronary artery bypass grafting (CABG)
























Heart Lung Machine





















Off-Pump Coronary Artery Bypass (OPCAB)



Use of Cardiopulmonary Bypass in Patients Undergoing CABG


Recommendations for Use of Cardiopulmonary Bypass in Patients Undergoing CABG

Referenced studies that support the recommendations are summarized in Online Data Supplement 40.

COR	LOE	Recommendations
2 a	B-R	1. In patients with significant calcification of the aorta, the use of techniques to avoid aortic manipulation (off-pump techniques or beating heart) is reasonable to decrease the incidence of perioperative stroke when performed by experienced surgeons.
2b	B-R	2. In patients with significant pulmonary disease, off-pump surgery may be reasonable to reduce perioperative risk when performed by experienced surgeons.

Procedure

- ☐ Median sternotomy of varying sizes.
 ☐ Depending on the physiology of the patient, the smallest incision will be made.
 ☐ Arteries or veins can be harvested from the patients chest wall, arm, and or leg.
- ☐ Betablockers are used to slow the heart rate.
- Deep pericardial sutures and the use of specialized instruments to prop the heart in a position that will allow the surgeon to access occluded arteries.



Instrumentation

□Octopus Device

- Has multiple small suction cups that are applied to the heart surface.
- ■When suction is turned on, the cups stick to the surface, and hold the heart steady, with movement being less than 1 mm.

□Star fish Device

☐ When suction is turned on, the cups stick to the surface, and hold the heart steady







12/4/2023 Fourth Year Cardiovascu








Fourth Year Cardiovascular System Lectures








12/4/2023

Fourth Year Cardiovascular System Lectures





Source: Lawrence H. Cohn, David H. Adams:
Cardiac Surgery in the Adult, Fifth Edition
Copyright © McGraw-Hill Education. All rights reserved.
Lectures






Figure 2. Positioning device (Starfish) and tissue stabilizer device on the epicardial surface




Antiplatelet Therapy in Patients After CABG








Beta Blockers in Patients After Revascularization








Abbreviations: CABG indicates coronary artery bypass grafting; LV, left ventricle; and SIHD, stable ischemic heart disease.

Focus on Perioperative Considerations in Patients Undergoing CABG and Outcomes



Antithrombotic Therapy

For patients undergoing CABG, establishment of multidisciplinary, evidence-based perioperative management programs is recommended to optimize analgesia, minimize opioid exposure, prevent complications and to reduce time to extubation, length of stay, and healthcare costs. (Class 1)



Abbreviations: CABG indicates coronary artery bypass grafting; CNS, central nervous system; CV, cardiovascular disease; LOS, length of stay; SIHD, stable ischemic heart disease; STEMI, ST segment elevation myocardial infarction; and TEE, transesophageal echo.

Decrease Post-operative Deep Sternal Wound Infections



Intraop + Postop Target Serum Glucose Level:

<180mg/dL (Class 1)



Administer IV insulin continuous infusion



AVOID hypoglycemia

Click here for more best practices



Abbreviations: IV indicates intravenous; and SWI, sternal wound infections.

- Indication For Surgery
- Preoperative Evaluation
- Conduits decision
- Operation Decision
- ERAS



2021 Guideline for Coronary Artery Revascularization



Treatment decisions with regard to coronary revascularization in patients with coronary artery disease should be based on clinical indications, REGARDLESS OF SEX, RACE, OR ETHNICITY, because there is no evidence that some patients benefit less than others, and efforts to reduce disparities of care are warranted.



In patients being considered for coronary revascularization for whom the optimal treatment strategy is unclear, a multidisciplinary HEART TEAM approach is recommended. Treatment decisions should be patient centered, incorporate patient preferences and goals, and include shared decisionmaking.



Patients with significant LEFT MAIN DISEASE, SURGICAL REVASCULARIZATION is indicated to improve survival relative to that likely to be achieved with medical therapy. Percutaneous revascularization is a reasonable option to improve survival, compared with medical therapy, in selected patients with low to medium anatomic complexity of coronary artery disease and left main disease that is equally suitable for surgical or percutaneous revascularization.



Updated evidence from contemporary trials supplement older evidence with regard to mortality benefit of revascularization in patients with stable ischemic heart disease, normal left ventricular ejection fraction, and triplevessel coronary artery disease. Surgical revascularization may be reasonable to improve survival. A survival benefit with percutaneous revascularization is uncertain. Revascularization decisions are based on consideration of disease complexity, technical feasibility of treatment, and a Heart Team discussion.



The use of a RADIAL ARTERY as a surgical revascularization conduit is preferred to the use of a saphenous vein conduit to bypass the second most important target vessel with significant stenosis after the left anterior descending coronary artery. Benefits include superior patency, reduced adverse cardiac events, and improved survival.



Top 10 Take Home Messages

Revascularization decisions in patients with diabetes and multivessel coronary artery disease are optimized by the use of a Heart Team approach. Patients with DIABETES WHO HAVE TRIPLE-VESSEL DISEASE SHOULD UNDERGO SURGICAL REVASCULARIZATION; percutaneous coronary intervention may be considered if they are poor candidates for surgery.

Thank You for Your Attention

V2

We added links for the vedioes in the slides, you can watch them by clicking on the vedio itself